vs

Side-by-side financial comparison of BYLINE BANCORP, INC. (BY) and Core Laboratories Inc. (CLB). Click either name above to swap in a different company.

Core Laboratories Inc. is the larger business by last-quarter revenue ($121.8M vs $112.4M, roughly 1.1× BYLINE BANCORP, INC.). BYLINE BANCORP, INC. runs the higher net margin — 33.4% vs 4.2%, a 29.2% gap on every dollar of revenue. On growth, BYLINE BANCORP, INC. posted the faster year-over-year revenue change (9.0% vs -1.4%). Over the past eight quarters, BYLINE BANCORP, INC.'s revenue compounded faster (6.4% CAGR vs -3.4%).

Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

BY vs CLB — Head-to-Head

Bigger by revenue
CLB
CLB
1.1× larger
CLB
$121.8M
$112.4M
BY
Growing faster (revenue YoY)
BY
BY
+10.5% gap
BY
9.0%
-1.4%
CLB
Higher net margin
BY
BY
29.2% more per $
BY
33.4%
4.2%
CLB
Faster 2-yr revenue CAGR
BY
BY
Annualised
BY
6.4%
-3.4%
CLB

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BY
BY
CLB
CLB
Revenue
$112.4M
$121.8M
Net Profit
$37.6M
$5.1M
Gross Margin
Operating Margin
1.5%
Net Margin
33.4%
4.2%
Revenue YoY
9.0%
-1.4%
Net Profit YoY
33.0%
EPS (diluted)
$0.83
$0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BY
BY
CLB
CLB
Q1 26
$112.4M
$121.8M
Q4 25
$117.0M
$138.3M
Q3 25
$115.7M
$134.5M
Q2 25
$110.5M
$130.2M
Q1 25
$103.1M
$123.6M
Q4 24
$104.7M
$129.2M
Q3 24
$101.8M
$134.4M
Q2 24
$99.4M
$130.6M
Net Profit
BY
BY
CLB
CLB
Q1 26
$37.6M
$5.1M
Q4 25
$34.5M
$4.9M
Q3 25
$37.2M
$14.2M
Q2 25
$30.1M
$10.6M
Q1 25
$28.2M
$-154.0K
Q4 24
$30.3M
$7.4M
Q3 24
$30.3M
$11.7M
Q2 24
$29.7M
$9.0M
Gross Margin
BY
BY
CLB
CLB
Q1 26
Q4 25
20.8%
Q3 25
22.0%
Q2 25
20.3%
Q1 25
19.5%
Q4 24
17.8%
Q3 24
20.5%
Q2 24
21.2%
Operating Margin
BY
BY
CLB
CLB
Q1 26
1.5%
Q4 25
40.1%
11.5%
Q3 25
43.1%
15.6%
Q2 25
35.2%
11.7%
Q1 25
36.4%
3.6%
Q4 24
38.6%
11.0%
Q3 24
39.3%
14.7%
Q2 24
40.4%
12.3%
Net Margin
BY
BY
CLB
CLB
Q1 26
33.4%
4.2%
Q4 25
34.1%
3.6%
Q3 25
32.1%
10.6%
Q2 25
27.2%
8.2%
Q1 25
27.4%
-0.1%
Q4 24
34.3%
5.7%
Q3 24
29.8%
8.7%
Q2 24
29.9%
6.9%
EPS (diluted)
BY
BY
CLB
CLB
Q1 26
$0.83
$0.11
Q4 25
$0.77
$0.11
Q3 25
$0.82
$0.30
Q2 25
$0.66
$0.22
Q1 25
$0.64
$0.00
Q4 24
$0.68
$0.15
Q3 24
$0.69
$0.25
Q2 24
$0.68
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BY
BY
CLB
CLB
Cash + ST InvestmentsLiquidity on hand
$198.4M
$22.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.3B
$275.1M
Total Assets
$9.9B
$587.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BY
BY
CLB
CLB
Q1 26
$198.4M
$22.8M
Q4 25
$149.1M
$22.7M
Q3 25
$259.0M
$25.6M
Q2 25
$218.3M
$31.2M
Q1 25
$421.3M
$22.1M
Q4 24
$563.1M
$19.2M
Q3 24
$452.6M
$21.5M
Q2 24
$730.5M
$17.7M
Total Debt
BY
BY
CLB
CLB
Q1 26
Q4 25
$110.3M
Q3 25
$114.1M
Q2 25
$124.6M
Q1 25
$124.4M
Q4 24
$126.1M
Q3 24
$139.9M
Q2 24
$147.6M
Stockholders' Equity
BY
BY
CLB
CLB
Q1 26
$1.3B
$275.1M
Q4 25
$1.3B
$266.0M
Q3 25
$1.2B
$271.3M
Q2 25
$1.2B
$261.3M
Q1 25
$1.1B
$253.4M
Q4 24
$1.1B
$246.6M
Q3 24
$1.1B
$250.7M
Q2 24
$1.0B
$240.3M
Total Assets
BY
BY
CLB
CLB
Q1 26
$9.9B
$587.7M
Q4 25
$9.7B
$584.0M
Q3 25
$9.8B
$591.4M
Q2 25
$9.7B
$602.1M
Q1 25
$9.6B
$591.5M
Q4 24
$9.5B
$585.1M
Q3 24
$9.4B
$600.5M
Q2 24
$9.6B
$597.8M
Debt / Equity
BY
BY
CLB
CLB
Q1 26
Q4 25
0.41×
Q3 25
0.42×
Q2 25
0.48×
Q1 25
0.49×
Q4 24
0.51×
Q3 24
0.56×
Q2 24
0.61×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BY
BY
CLB
CLB
Operating Cash FlowLast quarter
$4.0M
Free Cash FlowOCF − Capex
$517.0K
FCF MarginFCF / Revenue
0.4%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.77×
TTM Free Cash FlowTrailing 4 quarters
$22.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BY
BY
CLB
CLB
Q1 26
$4.0M
Q4 25
$140.3M
$7.9M
Q3 25
$38.3M
$8.5M
Q2 25
$16.3M
$13.9M
Q1 25
$27.1M
$6.7M
Q4 24
$175.2M
$20.6M
Q3 24
$19.8M
$13.1M
Q2 24
$40.1M
$17.1M
Free Cash Flow
BY
BY
CLB
CLB
Q1 26
$517.0K
Q4 25
$136.3M
$5.0M
Q3 25
$38.0M
$6.5M
Q2 25
$15.2M
$10.4M
Q1 25
$25.0M
$3.9M
Q4 24
$171.2M
$17.4M
Q3 24
$19.1M
$10.4M
Q2 24
$39.4M
$14.3M
FCF Margin
BY
BY
CLB
CLB
Q1 26
0.4%
Q4 25
116.5%
3.6%
Q3 25
32.8%
4.8%
Q2 25
13.7%
8.0%
Q1 25
24.3%
3.1%
Q4 24
163.5%
13.4%
Q3 24
18.8%
7.7%
Q2 24
39.7%
10.9%
Capex Intensity
BY
BY
CLB
CLB
Q1 26
Q4 25
3.4%
2.1%
Q3 25
0.3%
1.5%
Q2 25
1.0%
2.7%
Q1 25
2.0%
2.3%
Q4 24
3.8%
2.5%
Q3 24
0.6%
2.0%
Q2 24
0.7%
2.2%
Cash Conversion
BY
BY
CLB
CLB
Q1 26
0.77×
Q4 25
4.06×
1.61×
Q3 25
1.03×
0.60×
Q2 25
0.54×
1.31×
Q1 25
0.96×
Q4 24
5.78×
2.78×
Q3 24
0.65×
1.12×
Q2 24
1.35×
1.90×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons